findmyKOL
Clinical trialNCT07592858Not, yet, recruitingPhase 2Interventional

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

SponsorUniversity of Rhode IslandEnrollment50Burn Pit ExposureEnvironmental ExposuresForever ChemicalsHyperlipidemia (E.G., Hypercholesterolemia)Hyperlipidemias, Hypercholesterolemia, Mixed DyslipidemiaMilitary Exposure+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix \> 20 ng/ml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Robley Rex Va Medical Center

    Louisville, Kentucky, United States

    Matthew Cave, MD
  • Va Maine Healthcare System

    Augusta, Maine, United States

    Angela Slitt, PhDRodney Sparks, MD
  • Va Maine Healthcare System

    Augusta, Maine, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jul 2026
Primary completion
30 Apr 2029
Completion
29 Sept 2029
Last update posted
18 May 2026
Registered enrollment
50
Registry id
NCT07592858

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.